NASDAQ$EYPT
EyePoint Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Announced financial results for the second quarter ended June 30, 2022.
EyePoint Pharmaceuticals reported a net product revenue of $11.3 million in Q2 2022, a 30% increase from Q2 2021. The company's total net revenue was $11.6 million compared to $9.0 million for the quarter ended June 30, 2021.
- First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD).
- Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists (ASRS) 2022 Annual Meeting.
- Announced in conjunction with OcuMension Therapeutics, approval of New Drug Application by China’s National Medical Products Administration (NMPA) for YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
- Net product revenue of $11.3 million in Q2 2022; a 30% increase from Q2 2021.
Headline financials
Revenue & EPS history
EyePoint Pharmaceuticals · Revenue · Quarterly
$11.6M
Revenue by segment
EyePoint Pharmaceuticals · $11.6M total across 2 segments · Q2 2022
- Product sales, net$11.3M+29.5%97.4%
- License and Royalties$300K+9.1%2.6%
Forward guidance
We expect the cash, cash equivalents and investments on hand on June 30, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.4%
Avg return
Earnings day
-1.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
48%
28 / 58 earnings
Positive
+21.1%
Q3 2023
Best reaction
-37.2%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +1.9% | -11.9% | |
| Q4 2025 | -1.9% | -14.5% | -26.9% | |
| Q3 2025 | -11.0% | -8.4% | +43.2% | |
| Q1 2025 | -2.2% | -6.4% | +43.0% | |
| Q4 2024 | +8.2% | +16.6% | -24.2% | |
| Q3 2024 | -3.7% | -8.0% | -27.9% | |
| Q2 2024 | +1.6% | -7.3% | -11.6% | |
| Q1 2024 | +6.7% | +2.9% | -23.3% | |
| Q4 2023 | -5.2% | -11.4% | -21.2% | |
| Q3 2023 | +21.1% | +26.7% | +9.8% | |
| Q2 2023 | -1.3% | -2.6% | -17.2% | |
| Q1 2023 | +4.5% | -0.3% | -7.9% | |
| Q4 2022 | +2.8% | -0.9% | -7.3% | |
| Q3 2022 | -1.3% | -3.5% | -37.5% | |
| Q2 2022 | +13.3% | +14.2% | -0.2% | |
| Q1 2022 | -4.9% | -19.5% | -23.8% | |
| Q4 2021 | +16.6% | +34.3% | +23.9% | |
| Q3 2021 | +10.1% | +26.1% | +18.6% | |
| Q2 2021 | +6.5% | +8.3% | +28.7% | |
| Q1 2021 | -8.1% | -14.8% | -12.0% | |
| Q4 2020 | -18.6% | -12.4% | -6.8% | |
| Q3 2020 | -7.5% | +10.0% | +30.0% | |
| Q2 2020 | -8.2% | -6.8% | -32.9% | |
| Q1 2020 | -3.3% | -2.2% | -8.9% | |
| Q4 2019 | -11.1% | -27.1% | -47.2% | |
| Q3 2019 | -37.2% | -41.6% | -35.1% | |
| Q2 2019 | +11.9% | +3.2% | +20.6% | |
| Q4 2018 | -3.5% | +2.2% | +41.0% | |
| Q3 2018 | +6.7% | -15.9% | -4.6% | |
| Q2 2018 | -2.7% | -5.5% | +12.7% | |
| Q1 2018 | -2.4% | +9.5% | +0.8% | |
| Q4 2017 | +1.6% | -5.5% | -3.1% | |
| Q3 2017 | +16.6% | +17.8% | +33.1% | |
| Q2 2017 | +4.1% | +5.3% | +0.0% | |
| Q1 2017 | +1.0% | -2.0% | -11.2% | |
| Q4 2016 | +1.6% | -4.1% | -35.7% | |
| Q3 2016 | +0.7% | — | — | |
| Q2 2016 | -10.1% | — | — | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -1.3% | — | — | |
| Q3 2015 | -12.3% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | -1.5% | — | — | |
| Q3 2014 | +2.2% | — | — | |
| Q2 2014 | +4.6% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q3 2012 | +2.1% | — | — | |
| Q4 2010 | -0.6% | — | — | |
| Q4 2012 | +3.1% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -6.9% | — | — | |
| Q3 2011 | -5.5% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q3 2010 | -1.7% | — | — | |
| Q1 2010 | -4.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro